logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 20 of 777 Items
Showing 1 - 20 of 777 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Concomitant splenic tuberculosis and Epstein–Barr virus-related T-cell leukemia/lymphoma in a 28-year-old pregnant woman in South Sudan

Wild HB, Aumuller J, Kuei J, Simon M, Palm A,  et al.
2025-06-04 • American Journal of Tropical Medicine and Hygiene
2025-06-04 • American Journal of Tropical Medicine and Hygiene

This case report presents a rare instance of concomitant splenic tuberculosis (TB), Epstein–Barr virus (EBV)-related T-cell leukemia/lymphoma, and malaria in a 28-year-old pregnant wo...

Journal Article
|
Research

End of treatment and 12-month post-treatment outcomes in patients treated with all-oral regimens for rifampicin-resistant tuberculosis in Ukraine: a prospective cohort study

Fardhdiani V, Trush O, Lytvynenko N, Pylypchuk S, Terleeva Y,  et al.
2025-05-23 • PLOS Global Public Health
2025-05-23 • PLOS Global Public Health

The World Health Organization has called for operational research on all-oral shorter regimens for rifampin-resistant and multidrug-resistant forms of tuberculosis (RR/MDR-TB). We fol...

Journal Article
|
Research

Body mass index trajectories and association with tuberculosis risk in a cohort of household contacts in Southern Africa

Larsson L, Calderwood CJ, Marambire ET, Held K, Banze D,  et al.
2025-04-28 • Clinical Infectious Diseases
2025-04-28 • Clinical Infectious Diseases

BACKGROUND

Studies have demonstrated an inverse log-linear relationship between body mass index (BMI) and tuberculosis incidence. However, a person’s BMI is dyn...

Journal Article
|
Research

COVID-19, tuberculosis, and HIV triad: a prospective observational study in ambulatory patients in Kenya, Uganda, and South Africa

Huerga H, Gouillou M, Ohler L, Taremwa IM, Akinyi M,  et al.
2025-04-23 • PLOS Global Public Health
2025-04-23 • PLOS Global Public Health

People living with HIV (PLHIV) have an increased risk of tuberculosis (TB) and severe COVID-19. TB and COVI...

Journal Article
|
Research

Enhancing tuberculosis (TB) case detection among hospitalized patients through lay health worker led screening: a before-and-after study in KwaZulu-Natal, South Africa

Bulti AB, Dumicho AY, Shigayeva A, Van Cutsem G, Steele SJ,  et al.
2025-04-23 • Scientific Reports
2025-04-23 • Scientific Reports

Tuberculosis (TB) among hospitalized patients is underdiagnosed. This study assessed systematic TB-screenin...

Journal Article
|
Research

Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens

Gotham D, Martin M, Barber MJ, Kazounis E, Batts C,  et al.
2025-04-23 • PLOS Global Public Health
2025-04-23 • PLOS Global Public Health

Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médec...

Journal Article
|
Case Report/Series

Concomitant splenic tuberculosis and Epstein-Barr virus-related T-cell leukemia/lymphoma in a 28-year-old pregnant woman in South Sudan

Wild HB, Aumuller J, Kuei J, Simon M, Palm A,  et al.
2025-04-15 • American Journal of Tropical Medicine and Hygiene
2025-04-15 • American Journal of Tropical Medicine and Hygiene

This case report presents a rare instance of concomitant splenic tuberculosis (TB), Epstein–Barr virus (EBV)-related T-cell leukemia/lymphoma, and malaria in a 28-year-old pregnant wo...

Journal Article
|
Research

Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis—experiences from Armenia

Ardizzoni E, Mulders W, De Diego Fuertes M, Hayrapetyan A, Mirzoyan A,  et al.
2025-04-09 • Antimicrobial Agents and Chemotherapy
2025-04-09 • Antimicrobial Agents and Chemotherapy

Risk factors for baseline bedaquiline (BDQ) resistance, amplification during treatment, and correlations with treatment outcomes are not fully understood. This cohort included Armenia...

Journal Article
|
Letter

Equitable access needed in clinical research

Dang G, Perrin C, Furin J
2025-03-28 • Science
2025-03-28 • Science
Journal Article
|
Commentary

Leveraging nutritional rehabilitation and tuberculosis programmes to tackle tuberculosis and severe acute malnutrition in children

Vonasek BJ, Marcy O, Armour J, Casenghi M, Cazes C,  et al.
2025-03-23 • Lancet Child and Adolescent Health
2025-03-23 • Lancet Child and Adolescent Health

Each day more than 500 children younger than 15 years die from tuberculosis. Considerable progress has been...

Journal Article
|
Commentary

Equitable, personalised medicine for tuberculosis: Treating patients, not diseases

Guglielmetti L, Panda S, Abubakirov A, Salahuddin N, Perrin C,  et al.
2025-03-21 • Lancet Respiratory Medicine
2025-03-21 • Lancet Respiratory Medicine
Journal Article
|
Commentary

Scanned: The global investments in computer-aided detection and ultraportable X-ray for tuberculosis

Min J, Halton J, Villegas C, Chua A, Hewison C,  et al.
2025-03-17 • PLOS Global Public Health
2025-03-17 • PLOS Global Public Health
Journal Article
|
Research

Bedaquiline resistance and treatment outcomes among patients with tuberculosis previously exposed to bedaquiline in India: A multicentric retrospective cohort study

Singla R, Khan S, Silsarma A, Chavan V, Mahajan R,  et al.
2025-03-13 • Clinical Infectious Diseases
2025-03-13 • Clinical Infectious Diseases

BACKGROUND

Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. Th...

Journal Article
|
Editorial

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

Kuksa L, Andrejak C, Haecker B, Bothamley G, Calcagno A,  et al.
2025-03-01 • IJTLD OPEN
2025-03-01 • IJTLD OPEN

Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approve...

Journal Article
|
Research

The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings - A prospective cohort study in Belarus and Uzbekistan

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A,  et al.
2025-02-18 • Clinical Infectious Diseases
2025-02-18 • Clinical Infectious Diseases

BACKGROUND

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...

Journal Article
|
Research

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R,  et al.
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article
|
Letter

Sustained treatment success at 12 months for drug-resistant TB patients on concomitant bedaquiline-delamanid

Chavan V, Silsarma A, Mahajan R, Khan S, Singh P,  et al.
2025-02-01 • IJTLD OPEN
2025-02-01 • IJTLD OPEN
Journal Article
|
Research

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M,  et al.
2025-02-01 • Lancet Global Health
2025-02-01 • Lancet Global Health

BACKGROUND

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...

Journal Article
|
Research

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A,  et al.
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Journal Article
|
Research

Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data

Pelzer PT, Stuck L, Martinez L, Richards AS, Acuña-Villaorduña C,  et al.
2024-12-19 • Lancet Microbe
2024-12-19 • Lancet Microbe

BACKGROUND

Tuberculosis vaccine trials using disease as the primary endpoint are large, time consuming, and expensive. An earlier immunological measure of the p...